Manipulating the blood labyrinth barrier with mannitol to prevent cisplatin-induced hearing loss

被引:9
作者
Noman, Ayesha [1 ,2 ]
Mukherjee, Subhendu [2 ]
Le, Trung N. [1 ,2 ,3 ,4 ]
机构
[1] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada
[4] Dept Otolaryngol Head & Neck Surg, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
关键词
Cisplatin ototoxicity; Cochlear pharmacokinetics of cisplatin; Manipulating the blood labyrinth barrier; Antioxidant protection against; cisplatin-induced hearing loss; Mannitol; N-ACETYLCYSTEINE; SODIUM THIOSULFATE; INDUCED OTOTOXICITY; IN-VIVO; NEUROTOXICITY; PROTECTION; HEAD; PHARMACOKINETICS; NEPHROTOXICITY; OTOPROTECTION;
D O I
10.1016/j.heares.2022.108646
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Cisplatin, a chemotherapeutic medication, remains in the cochlea indefinitely, causing permanent hearing loss. Mannitol, a diuretic medication, has been shown to increase the permeability of the blood labyrinth barrier (BLB). We hypothesize that mannitol increases the permeability of the BLB and therefore increases the rate of entry and egression of cisplatin and entry of otoprotective agents. Rats treated with cisplatin ( t = 0) were given mannitol at either t = 0, t = 6 or t = 0,6 h. Another group of rats were treated with cisplatin with mannitol at 0 h and NAC/STS with and without mannitol at 6 h. Concurrent mannitol ( t = 0) transiently increased cisplatin entry into the inner ear and exacerbated cisplatin-induced hearing loss. Delayed mannitol ( t = 6) did not significantly increase cisplatin entry into the inner ear and pre-served inner ear functionality and structure. Additional-delayed mannitol ( t = 0,6) showed that the 2nd dose of mannitol prevented exacerbation of cisplatin with mannitol-induced hearing loss. A combination of delayed NAC/STS with mannitol ( t = 6) was better than NAC/STS ( t = 6) alone at providing partial to full protection against cisplatin with mannitol-induced hearing loss. In conclusion, mannitol injections at t = 6 h reduced cisplatin ototoxicity (instead of exacerbating cisplatin ototoxicity at t = 0 h), and it en-hanced the otoprotective efficacy of antioxidants. This may provide an important therapeutic strategy to prevent cisplatin-induced hearing loss, a direct implication in protection against hearing loss in cisplatin chemotherapy.(c) 2022 Published by Elsevier B.V.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study [J].
Marshak, Tal ;
Steiner, Mariana ;
Kaminer, Margalith ;
Levy, Levana ;
Shupak, Avi .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2014, 150 (06) :983-990
[42]   Pharmacological treatment with annexin A1-derived peptide protects against cisplatin-induced hearing loss [J].
Sena, Leticia S. ;
Sasso, Gisela R. S. ;
Sanches, Jose Marcos ;
Franco, Paulo C. ;
Azevedo, Marisa F. ;
Oliani, Sonia M. ;
Gil, Cristiane D. .
TOXICOLOGY LETTERS, 2022, 363 :27-35
[43]   Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study [J].
El Hamamsy, Manal ;
Kamal, Noha ;
Bazan, Naglaa Samir ;
El Haddad, Mostafa .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (06) :1539-1547
[44]   Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study [J].
Manal El Hamamsy ;
Noha Kamal ;
Naglaa Samir Bazan ;
Mostafa El Haddad .
International Journal of Clinical Pharmacy, 2018, 40 :1539-1547
[45]   Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials [J].
Minasian, Lori M. ;
Frazier, A. Lindsay ;
Sung, Lillian ;
O'Mara, Ann ;
Kelaghan, Joseph ;
Chang, Kay W. ;
Krailo, Mark ;
Pollock, Brad H. ;
Reaman, Gregory ;
Freyer, David R. .
CANCER MEDICINE, 2018, 7 (07) :2951-2959
[46]   The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss [J].
Ghosh, Sumana ;
Sheth, Sandeep ;
Sheehan, Kelly ;
Mukherjea, Debashree ;
Dhukhwa, Asmita ;
Borse, Vikrant ;
Rybak, Leonard P. ;
Ramkumar, Vickram .
FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
[47]   Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients [J].
Viglietta, Vissia ;
Shi, Fuxin ;
Hu, Qi-Ying ;
Ren, Yong ;
Keilty, John ;
Wolff, Heather ;
McCarthy, Ryan ;
Kropp, Jason ;
Weber, Pete ;
Soglia, John .
INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) :1463-1471
[48]   Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig [J].
Wang, J ;
Faulconbridge, RVL ;
Fetoni, A ;
Guitton, MJ ;
Pujol, R ;
Puel, JL .
NEUROPHARMACOLOGY, 2003, 45 (03) :380-393
[49]   Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity [J].
Takagi, Ayaka ;
Miyoshi, Takanori ;
Hayashi, Toshinobu ;
Koizumi, Hinako ;
Tsumagari, Kyouichi ;
Yokota, Chiaki ;
Nakano, Takafumi ;
Matsuo, Koichi ;
Egawa, Takashi .
SCIENTIFIC REPORTS, 2024, 14 (01)
[50]   Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review [J].
Rose, Olaf ;
Croonenberg, Tim ;
Clemens, Stephanie ;
Hinteregger, Tobias ;
Eppacher, Stefanie ;
Huber-Cantonati, Petra ;
Garcia-Miralles, Marta ;
Liuni, Raffaella ;
Dossena, Silvia .
ANTIOXIDANTS, 2024, 13 (12)